Analysts Set Expectations for ATNM Q1 Earnings

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) – Research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Actinium Pharmaceuticals in a research report issued on Tuesday, March 31st. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.22) per share for the quarter. The consensus estimate for Actinium Pharmaceuticals’ current full-year earnings is ($1.41) per share. HC Wainwright also issued estimates for Actinium Pharmaceuticals’ Q2 2026 earnings at ($0.25) EPS, Q3 2026 earnings at ($0.29) EPS and Q4 2026 earnings at ($0.33) EPS.

Separately, Stephens restated an “overweight” rating and set a $5.00 price objective on shares of Actinium Pharmaceuticals in a research report on Tuesday. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $4.50.

Actinium Pharmaceuticals Stock Up 0.5%

Shares of ATNM stock opened at $1.00 on Wednesday. The company has a 50 day moving average price of $1.14 and a 200-day moving average price of $1.35. Actinium Pharmaceuticals has a 52 week low of $0.95 and a 52 week high of $1.95. The firm has a market capitalization of $31.05 million, a PE ratio of -0.72 and a beta of -0.31.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Actinium Pharmaceuticals by 0.9% in the third quarter. Vanguard Group Inc. now owns 1,384,543 shares of the company’s stock worth $2,215,000 after purchasing an additional 12,703 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Actinium Pharmaceuticals by 35.4% during the 4th quarter. Renaissance Technologies LLC now owns 390,784 shares of the company’s stock valued at $531,000 after purchasing an additional 102,154 shares during the last quarter. Two Sigma Investments LP lifted its stake in shares of Actinium Pharmaceuticals by 403.4% in the 3rd quarter. Two Sigma Investments LP now owns 234,293 shares of the company’s stock worth $375,000 after purchasing an additional 187,748 shares during the period. Jane Street Group LLC bought a new position in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $306,000. Finally, Marshall Wace LLP purchased a new position in shares of Actinium Pharmaceuticals in the second quarter worth approximately $137,000. Institutional investors own 27.50% of the company’s stock.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.